Sun Pharma Advanced Research SPARC

Till 01:44 PM; as many as a combined 27.7 million equity shares representing 8.5 per cent of the total equity of pharmaceutical company have changed hands on the NSE and BSE.

Sun Pharma Advanced Research share price tanked 20 per centa after Vibozilimod (SCD-044) studies failed to meet the primary endpoint

After a period of being net buyers in the first half of the fiscal year, FIIs reversed their stance in the second half, unloading over ₹1.5 lakh crore worth of Indian equities

These 5 smallcap stocks have given a breakout on the hourly time-frame hence are expected to trade with a positive bias in the near-term, suggests the technical charts.

In the medium term, SPARC's pipeline has several inflexion points that can drive significant value for the company.

PROSEEK, one of the largest phase-2 studies in early Parkinson's disease, encompassed 84 sites across the United States, Europe, and India

Sun Pharma Advanced Research Company Ltd on Monday said its net loss widened to Rs 81.99 crore in the fourth quarter ended March 2023, impacted by higher expenses. The company had posted a net loss of Rs 71.05 crore in the same period previous fiscal, Sun Pharma Advanced Research Company said in a regulatory filing. Its revenue from operations stood at Rs 47.69 crore compared to Rs 25.24 crore in the year-ago period, it added. The total expenses in the fourth quarter were higher at Rs 140.41 crore against Rs 96.51 crore in the same period a year ago. The company further said that during the quarter, it paused the development of the 'SC0-120' programme due to changing clinical landscape as a result of which it has made provision for committed costs for this programme estimated at Rs 27 crore. For FY23, the company said its net loss stood at Rs 222.58 crore. It was at Rs 203.4 crore in FY23. The revenue from operations in FY23 was Rs 238.78 crore compared to Rs 137.25 crore in FY22

Shares of Sun Pharma on Friday jumped over 5 per cent after the company reported a 43 per cent rise in consolidated net profit for the June quarter. The stock climbed 5.45 per cent to settle at Rs 943.55 apiece on the BSE. During the day, it rallied 6.31 per cent to Rs 951.25. On the NSE, it jumped 5.44 per cent to Rs 943.60 apiece. In volume terms, 4.88 lakh shares were traded on the BSE and over 1.13 crore shares on the NSE during the day. On Friday, Sun Pharma reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. The 30-share BSE barometer jumped 712.46 points or 1.25 per cent to settle at 57,570.25.

Stocks hitting a 52-week high or new all-time high early in the year tend to have more legs for an upside for the rest of the year.

Telecom shares may be in demand on credit of bank guarantee to the telcos

Sun Pharma Advanced Research Company (SPARC) on Wednesday said it will seek shareholders' approval to raise up to Rs 1,800 crore through various modes, including issue of equity shares and securities

Alembic Pharma and Dr Reddy's Labs plunged 12% and 11%, respectively in intra-day trade post their June quarter results

Sun Pharma Advanced Research Company on Thursday said it has raised over Rs 1,112 crore by way of issuing warrants to the company's promoter Dilip Shanghvi and other entities

Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company''s strategy of developing the specialty business as an additional growth engine has started delivering results

Among the sectoral indices on the NSE, Nifty FMCG gained the most - up nearly 2 per cent to 30,986 points, followed by Nifty Metal and Nifty Auto indices

The company has received a Complete Response Letter (CRL) from the USFDA for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).

In August this year, Abraxis Biosciences LLC had alleged that SPARC's filing of NDA or Taclantis injection is an act of infringement of the Orange Book listed patents for Abraxane.

Shares of SPARC were trading at Rs 146.7 apiece, up 2.34% on the BSE

Delay in commercialisation of near-term opportunities to hurt SPARC, Sun Pharma

Sun Pharma's research arm will initiate site transfer for its anti epilepsy drug Elepsia and eye drop Xelpros after failing to receive product approval from the US drug regulator.Both the products were filed from Sun Pharma's Halol plant which received US Food and Drug Administration warning letter in 2015. As such the the two products did not receive approval. Sun Pharmaceutical Advanced Research Company (SPARC) now plans to resubmit its application for product approval to the regulator from an alternate site, chief executive officer Anil Raghavan said today.SPARC had licensed these two under development drugs to Sun Pharma in lieu of an upfront payment and royalties on sales. But delays in commercialisation of the two drugs led to widening of loss to Rs 120 crore in FY 17. The company's cash flow too was impacted as it continued to invest in clinical development.The company's stock slipped 7 per cent today to close at Rs 392.95 today. On a year to date basis however the stock has .